SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Alzheimer's Disease and Other Dementias®
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Aupperle, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aupperle, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Bullying
*Dementia
*Psychotic Disorders
Hazardous Substances DB
*HALOPERIDOL
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Management of aggression, agitation, and psychosis in dementia: Focus on atypical antipsychotics

Peter Aupperle, MD, MPH

Division of Geriatric Psychiatry, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey

The behavioral and psychological symptoms of dementia (BPSD), such as psychosis, agitation, or aggression have a considerable negative impact on the quality of life of both patients and their caregivers. Multiple studies have demonstrated that atypical antipsychotics are efficacious in the treatment of the aggressive and psychotic symptom clusters, and here we review their use in this indication. Because of the safety concerns associated with the use of atypical antipsychotics in this population, these drugs must be usedjudiciously. For patients with severe BPSD such as psychosis, agitation, or aggression, for whom there are few options, atypical antipsychotics, particularly risperidone and olanzapine, should be considered.

Key Words: dementia • BPSD • atypical antipsychotic

References

  • 1. Finkel SI: Introduction to behavioral and psychological symptoms of dementia (BPSD). Int JGeriatrPsychiatry. 2000; 15(Suppl 1): S2-S4.
  • 2. Small GW, Rabins PV, Barry PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAAM. 1997; 278: 1363-1371.
  • 3. Finkel SI: Behavioral and psychological symptoms of dementia: A current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001; 62(Suppl 21): 3-6.
  • 4. Hemels ME, Lanctot KL, Iskedjian M, et al.: Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs Aging. 2001; 18: 527-550.[CrossRef][Medline] [Order article via Infotrieve]
  • 5. Cummings JL, Mega M, Gray K, et al.: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-2314.[Abstract/Free Full Text]
  • 6. Cohen-Mansfield J: Nonpharmacologic interventions for inappropriate behaviors in dementia. Am J Geriatr Psychiatry. 2001; 9: 361-381.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 7. McShane RH: What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychogeriatr. 2000; 12(Suppl 1): 147-153.[CrossRef]
  • 8. Tariot PN, Blazina L: The psychopathology of dementia. In Morris TC (ed): Handbook of Dementing Illnesses. New York: Marcel Dekker, 1994.
  • 9. Steele C, Rovner B, Chase GA, et al.: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Ain J psychiatry. 1990; 147: 1049-1051.
  • 10. Balestreri L, Grossberg A, Grossberg GT: Behavioral and psychological symptoms of dementia as a risk factor for nursing home placement. nt Psychogeriatr. 2000; 12(Suppl 1): 59-62.[CrossRef]
  • 11. Teri L, Rabins P. Whitehouse P. et al.: Management of behavior disturbance in Alzheimer disease: Current knowledge and future directions. Alzheimer Dis Assoc Disord. 1992; 6: 77-88.[Web of Science][Medline] [Order article via Infotrieve]
  • 12. Herrmann N, Lanctot KL, Naranjo CA: Behavioural disorders in demented elderly patients. CNS Drugs. 1996; 6: 280-300.
  • 13. De Deyn PP, Wirshing WC: Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001; 62(Suppl 21): 19-22.[Web of Science][Medline] [Order article via Infotrieve]
  • 14. Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48(Suppl): 9-15.[Web of Science][Medline] [Order article via Infotrieve]
  • 15. Cohen-Mansfield J: Conceptualization of agitation: Results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996; 8(Suppl 3): 309-315.[Medline] [Order article via Infotrieve]
  • 16. Dahlke F, Lohaus A, Gutzmann H: Reliability and clinical concepts underlying global judgments in dementia: Implications for clinical research. Psychopharmacol Bull. 1992; 28: 425-432.[Web of Science][Medline] [Order article via Infotrieve]
  • 17. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10: 799-812.[Web of Science]
  • 18. Herrmann N: Recommendations for the management of behavioral and psychological symptoms of dementia. Can JNeurol Sci. 2001; 28(Suppl 1): S96-S107.
  • 19. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA. 2005; 293: 596-608.[Abstract/Free Full Text]
  • 20. Gauthier S, Feldman H, Hecker J, et al.: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002; 14: 389-404.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 21. Paleacu D, Mazeh D, Mirecki I, et al.: Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol. 2002; 25: 313-317.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 22. Weiner MF, Martin-Cook K, Foster BM, et al.: Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry. 2000; 61: 487-492.[Medline] [Order article via Infotrieve]
  • 23. Tariot PN, Cummings JL, Katz IR, et al.: A randomized, doubleblind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. JAm Geriatr Soc. 2001; 49: 1590-1599.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 24. Wilcock G, Howe I, Coles H, et al.: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003; 20: 777-789.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 25. Suh GH, Yeon Jung H, Uk Lee C, et al.: A prospective, doubleblind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Therap. 2004; 26: 1608-1618.
  • 26. Cummings JL, Schneider L, Tariot PN, et al.: Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am JPsychiatry. 2004; 161: 532-538.
  • 27. Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-IO Study Group. Neurology. 2000; 54: 2269-2276.[Abstract/Free Full Text]
  • 28. Schneider LS, Pollock VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. JAm Geriatr Soc. 1990; 38: 553-563.[Web of Science][Medline] [Order article via Infotrieve]
  • 29. Zaudig M: A risk-benefit assessment of risperidone for the treatment of behavioral and psychological symptoms in dementia. Drug Safety. 2000; 23: 183-195.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 30. Lawlor B, Bhriain SN: Psychosis and behavioral symptoms of dementia: Defining the role of neuroleptic interventions. IntJGeriatr Psychiatry. 2001; 16(Suppl 1): S2-S6.
  • 31. Jeste DV, Rockwell E, Harris MJ, et al.: Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999; 7: 70-76.[Web of Science][Medline] [Order article via Infotrieve]
  • 32. Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999; 60: 107-115.[Web of Science][Medline] [Order article via Infotrieve]
  • 33. De Deyn PP, Rabheru K, Rasmussen A, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999; 53: 946-955.[Abstract/Free Full Text]
  • 34. Chan WC, Lam LC, Choy CN, et al.: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioral and psychological symptoms in Chinese dementia patients. IntJ Geriatr Psychiatry. 2001; 16: 1156-1162.
  • 35. Brodaty H, Ames D, Snowdon J, et al.: A randomized placebocontrolled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64: 134-143.[Web of Science][Medline] [Order article via Infotrieve]
  • 36. Suh GH, Son HG, Ju YS, et al.: A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry. 2004; 12: 509-516.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 37. De Deyn PP, Katz IR, Brodaty H, et al.: Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005; 107: 497-508.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 38. Street JS, Clark WS, Gannon KS, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebocontrolled trial. Arch Gen Psychiatry. 2000; 57: 968-976.[Abstract/Free Full Text]
  • 39. De Deyn PP, Carrrasco MM, Deberdt W, et al.: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004; 9: 115-126.
  • 40. Clark WS, Street JS, Feldman PD, et al.: The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2001; 62: 34-40.[Web of Science][Medline] [Order article via Infotrieve]
  • 41. Rainer MK, Mucke HA, Kruger-Rainer C, et al.: Zotepine for behavioral and psychological symptoms in dementia: An open-label study. CNS Drugs. 2004; 18: 49-55.[CrossRef][Medline] [Order article via Infotrieve]
  • 42. Fujikawa T, Takahashi T, Kinoshita A, et al.: Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology. 2004; 49: 201-204.[CrossRef][Medline] [Order article via Infotrieve]
  • 43. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2002; 16: 128-130.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 44. McManus DQ, Arvanitis LA, Kowalcyk BB: Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999; 60: 292-298.[Web of Science][Medline] [Order article via Infotrieve]
  • 45. Tariot PN, Salzman C, Yeung PP, ei al.: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therap. 2000; 22: 1068-1084.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 46. Ballard C, Margallo-Lana M, Juszczak E, et al.: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ. 2005; 330: 874-874.[Abstract/Free Full Text]
  • 47. De Deyn P, Jeste DV, Swanink R, et al.: Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: A randomized, placebo-controlled study. J Clin Psychopharmacol. 2005; 25: 463-467.[CrossRef][Medline] [Order article via Infotrieve]
  • 48. Baskys A: Lewy body dementia: The litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004; 65(Suppl 11): 16-22.
  • 49. Mulsant BH, Gharabawi GM, Bossie CA, et al.: Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004; 65: 1708-1714.[Medline] [Order article via Infotrieve]
  • 50. Gareri P, Cotroneo A, Lacava R, et al.: Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl. 2004; 9: 207-215.
  • 51. Fontaine CS, Hynan LS, Koch K, et al.: A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003; 64: 726-730.[Medline] [Order article via Infotrieve]
  • 52. Schneider LS, Tariot PN, Lyketsos CG; et al.: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9: 346-360.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 53. McShane R, Keene J, Gedling K, et al.: Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997; 314: 266-270.[Abstract/Free Full Text]
  • 54. Saxton J, McGonigle-Gibson K, Swihart A, et al.: Assessment of severely impaired patients: Description and validation of a new neuropsychological test battery. PsycholAssess. 1990; 2: 298-303.
  • 55. http.//www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 11, 2005.
  • 56. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA4. 2005; 294: 1934-1943.[Abstract/Free Full Text]
  • 57. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular adverse events in dementia trials. Can Med Assoc J. 2002; 167: 1269-1270.[Free Full Text]
  • 58. Wooltorton E. Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J 2004; 170: 1395-1395.[Free Full Text]
  • 59. Abilify package insert. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.; 2005.
  • 60. Herrmann N, Lanct6t KL. Do atypical antipsychotics cause stroke? CNSDrugs. 2005; 19: 91-103.
  • 61. Sleeper RB: Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother. 2005; 39: 1573-1576.[Abstract/Free Full Text]
  • 62. Zhao Q, Xie C, Pesco-Koplowitz L, et al.: Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol. 2003; 43: 180-186.[Abstract/Free Full Text]
  • 63. Weiser M, Rotmensch HH, Korczyn AD, et al.: A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int JGeriatr Psychiatry. 2002; 17: 343-346.[CrossRef]
  • 64. Huang F, Lasseter KC, Janssens L, et al.: Pharmacokinetic and safety assessments of galantamine and risperidone after thetwo drugs are administered alone and together. J Clin Pharmacol. 2002; 42: 1341-1351.[Abstract]

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 21, No. 2, 101-108 (2006)
DOI: 10.1177/153331750602100209
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Aupperle, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aupperle, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Bullying
*Dementia
*Psychotic Disorders
Hazardous Substances DB
*HALOPERIDOL
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement